
After FDA says no, Bayer bags EU nod for twice-yearly Eylea
Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases like wet age-related macular degeneration (AMD) with a new approval for Eylea 8mg. The European Commission has cleared the high-strength formulation of …